ZYNLONTA® (loncastuximab tesirine-lpyl) – Specific Gravity

Overview

- ZYNLONTA is supplied as a sterile, preservative-free, lyophilized powder in a single-dose vial for reconstitution and further dilution.[1]
- The specific gravity (density) of ZYNLONTA after reconstitution is 1.024 g/mL.[2]
- ADC Therapeutics does not recommend the Dosage and Administration of ZYNLONTA outside of what is found in the Prescribing Information. Please defer to your clinical judgment. See Relevant Prescribing information for additional information.

Literature Search

- A PubMed biomedical literature search conducted on April 4, 2025, yielded no further relevant data regarding the specific gravity (density) of ZYNLONTA.

Relevant Prescribing Information

Section 2: Dosage and Administration[1]

2.4: Reconstitution and Administration Instructions

Reconstitution of lyophilized ZYNLONTA

- Reconstitute each ZYNLONTA vial using 2.2 mL of Sterile Water for Injection, USP with the stream directed toward the inside wall of the vial to obtain a final concentration of 5 mg/mL.
- Swirl the vial gently until the powder is completely dissolved. *Do not shake*. *Do not expose to direct sunlight*.
- Inspect the reconstituted solution for particulate matter and discoloration. The solution should appear clear to slightly opalescent, colorless to slightly yellow. Do not use if the reconstituted solution is discolored, is cloudy, or contains visible particulates.
- Use reconstituted ZYNLONTA immediately. If not used immediately, store the reconstituted solution in the vial for up to 4 hours refrigerated at 2°C to 8°C (36°F to 46°F) or room temperature 20°C to 25°C (68°F to 77°F). *Do not freeze*.
- The product does not contain a preservative. Discard unused vial after reconstitution if the recommended storage time is exceeded.

Dilution in infusion bag

- Withdraw the required volume of reconstituted solution from the ZYNLONTA vial using a sterile syringe. Discard any unused portion left in the vial.
- Add the calculated dose volume of ZYNLONTA solution into a 50 mL infusion bag of **5% Dextrose Injection, USP**.
- Gently mix the intravenous bag by slowly inverting the bag. *Do not shake*.
- If not used immediately, store the diluted ZYNLONTA infusion solution refrigerated at 2°C to 8°C (36°F to 46°F) for up to 24 hours or at room temperature 20°C to 25°C (68°F to 77°F) for up to 8 hours. Discard diluted infusion bag if storage time exceeds these limits. *Do not freeze*.
- No incompatibilities have been observed between ZYNLONTA and intravenous infusion bags with product-contacting materials of polyvinylchloride (PVC), polyolefin (PO), and PAB® (copolymer of ethylene and propylene).

References

[1] ZYNLONTA® (loncastuximab tesirine-lpyl) FDA-approved Prescribing Information. October 2022.
[2] Data on File, Pharmaceutical Development. ADC Therapeutics.

ADC Therapeutics encourages all health care professionals to report any adverse events and product quality complaints to medical information at 855-690-0340. Please consult the ZYNLONTA Prescribing Information.